Raymond James analyst Danielle Brill downgraded FibroGen to Market Perform from Outperform with no price target after the company’s Phase 3 ZEPHYRUS-1 study did not meet the primary endpoint.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FGEN: